Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...
The approach relies on a specially engineered scaffold that links three naturally occurring cytokines known to promote immune memory.
FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 on leukemia cells.
A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...
A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...
Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results